KARD

Kardigan Inc

Jun 24 • 04:00PM ET

22.03

-0.21 -0.94 %

Healthcare • Biotechnology • USA • Small • NASD

Jun 22, 5:40 PMKardigan announces the closing of its IPO at $16 per share with underwriters fully exercising their option, bringing total gross proceeds to $460 million.

Held by: GSC TMED GDOC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	87.67M	Perf Week	-
Market Cap	1.93B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	2.26B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	0.14%
Book/sh	-3.43	P/C	6.73	EPS next 5Y	-	ROE	-	52W High	24.86 -11.38%	Perf Year	-
Cash/sh	3.27	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	16.25 35.57%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	4.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	9.42	EPS Q/Q	-	SMA20	-1.03%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-1.03%	Rel Volume	0.19	Prev Close	22.24
Employees	210	LT Debt/Eq	0.03	Earnings	-	SMA200	-1.03%	Avg Volume	2.44M	Price	22.03
IPO	Jun 18, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	471,733	Change	-0.94%

Jun-22-26 05:03PM	Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
Jun-18-26 02:03PM	Kardigan shares soar after Nasdaq debut (Investing.com)

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its "Cardiac Intelligence" platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Chief Technical Operations OfficerMr. Donald Mackenzie Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERNS PAUL L	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:20 PM
ARCH Venture Partners XIII, LL	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KARD

Kardigan Inc

Upgrade your Finviz experience